|
|
Blood, 15 June 2007, Vol. 109, No. 12, pp. 5346-5354.
Prepublished online as a Blood First Edition Paper on February 27, 2007; DOI 10.1182/blood-2006-10-051318.
 Previous Article | Table of Contents | Next Article 
IMMUNOBIOLOGY
CD4 cells can be more efficient at tumor rejection than CD8 cells
Ainhoa Perez-Diez1,
Nathalie T. Joncker3,
Kyungho Choi2,
William F. N. Chan4,
Colin C. Anderson4,5,
Olivier Lantz3, and
Polly Matzinger1
From the 1 Ghost Lab
2 Laboratory of Cellular and Molecular Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD;
3 Laboratoire d'Immunologie and U520 Institut National de la Santé et de la Recherche Médicale, Institute Curie, Paris, France; and
Departments of 4 Medical Microbiology & Immunology and
5 Surgery, University of Alberta, Edmonton, AB, Canada
Researchers designing antitumor treatments have long focused on eliciting tumor-specific CD8 cytotoxic T lymphocytes (CTL) because of their potent killing activity and their ability to reject transplanted organs. The resulting treatments, however, have generally been surprisingly poor at inducing complete tumor rejection, both in experimental models and in the clinic. Although a few scattered studies suggested that CD4 T "helper" cells might also serve as antitumor effectors, they have generally been studied mostly for their ability to enhance the activity of CTL. In this mouse study, we compared monoclonal populations of tumor-specific CD4 and CD8 T cells as effectors against several different tumors, and found that CD4 T cells eliminated tumors that were resistant to CD8-mediated rejection, even in cases where the tumors expressed major histocompatibility complex (MHC) class I molecules but not MHC class II. MHC class II expression on host tissues was critical, suggesting that the CD4 T cells act indirectly. Indeed, the CD4 T cells partnered with NK cells to obtain the maximal antitumor effect. These findings suggest that CD4 T cells can be powerful antitumor effector cells that can, in some cases, outperform CD8 T cells, which are the current "gold standard" effector cell in tumor immunotherapy.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Antitumor T-cell wars: do CD4s outwit CD8s?
- Ignacio Melero
Blood 2007 109: 5070-5071.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
P. Muranski, A. Boni, P. A. Antony, L. Cassard, K. R. Irvine, A. Kaiser, C. M. Paulos, D. C. Palmer, C. E. Touloukian, K. Ptak, et al.
Tumor-specific Th17-polarized cells eradicate large established melanoma
Blood,
July 15, 2008;
112(2):
362 - 373.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. L. Alderson, Q. Zhou, V. Berner, D. E. C. Wilkins, J. M. Weiss, B. R. Blazar, L. A. Welniak, R. H. Wiltrout, D. Redelman, and W. J. Murphy
Regulatory and Conventional CD4+ T Cells Show Differential Effects Correlating with PD-1 and B7-H1 Expression after Immunotherapy
J. Immunol.,
March 1, 2008;
180(5):
2981 - 2988.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Zhou, L. L'italien, D. Hodges, and X. M. Schebye
Pivotal Roles of CD4+ Effector T cells in Mediating Agonistic Anti-GITR mAb-Induced-Immune Activation and Tumor Immunity in CT26 Tumors
J. Immunol.,
December 1, 2007;
179(11):
7365 - 7375.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Perosa, E. Favoino, C. Vicenti, F. Merchionne, and F. Dammacco
Identification of an Antigenic and Immunogenic Motif Expressed by Two 7-Mer Rituximab-Specific Cyclic Peptide Mimotopes: Implication for Peptide-Based Active Immunotherapy
J. Immunol.,
December 1, 2007;
179(11):
7967 - 7974.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. N. Lalli, M. G. Strainic, F. Lin, M. E. Medof, and P. S. Heeger
Decay Accelerating Factor Can Control T Cell Differentiation into IFN-{gamma}-Producing Effector Cells via Regulating Local C5a-Induced IL-12 Production
J. Immunol.,
November 1, 2007;
179(9):
5793 - 5802.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
